about
physicians
new patient





WESTWOOD CARDIOLOGY

 

Westwood Cardiology regular participates in national and international clinical trials to help ensure that our patients have access to the most current therapies available.

 RESEARCH ACTIVITIES

Current Clinical Trials:

 

PROMINENT is a large 10,000 patient trial of Permafibrate in high risk type 2 diabetic patient with high triglycerides and low high-density lipoprotein cholesterol (HDL-C) looking at cardiovascular outcomes and risk reduction. This investigational agent has the effect of lowering triglyceride levels and may reduce cardiac events in high risk individuals.

 

ODYSSEY is a randomized, double-blind, placebo-controlled study to evaluate the effect of Alirocumab on the occurrence of cardiovascular events in patient who have recently experienced an acute coronary syndrome. Alirocumab is a human monoclonal antibody which significantly reduces LDL-cholesterol.

 

CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) will test whether reducing inflammation among men and women who have had a prior heart attack can reduce the risk of another cardiovascular event happening in the future. Canakinumab blocks the pro-inflammatory cytokine interleukin-1b. Patients with an elevated hsCRP may be candidates for enrollment in this important clinical trial.

 

CIRT (Cardiovascular Inflammation Reduction Trial) is a randomized, double-blind, placebo-controlled trial funded by the National Heart Lung and Blood Institute that will enroll 7000 patients who have either suffered a myocardial infarction in the past or have documented coronary blockages. The trial will evaluate whether low-dose methotrexate will reduce the rates of myocardial infarction, stroke, and cardiovascular death in patients with type 2 diabetes or metabolic syndrome, conditions assocated with an enhanced pro-inflammatory response.

 

Studies Concluded:

 

    ON TARGET/TRANSCEND is a large multi-center international study evaluating whether the combination of an ACE (angiotensin converting enzyme) inhibitor and ARB (angiotensin receptor blocker) is more effective than an ACE or ARB alone in reducing the risk of heart attack, stroke, heart failure or death in patients with heart disease or peripheral vascular disease.

 

HF ACTION is a large multi-center NIH study evaluating whether exercise can reduce mortality and hospitalization in patients with congestive heart failure.

 

IMPROVE HF is the largest heart failure quality improvement outpatient registry ever undertaken, that is designed to assess and improve heart failure treatment practices.

 

INTER-TRIAL is an NIH infrastructure project that we are participating with in coordination with Columbia University that is evaluating networks for optimal clinical research.

 

     CLOSURE I is an FDA-approved study to determine if non-surgical patch closure of a congenital heart defect (a patent foramen ovale or hole in the atrial wall) can prevent future stroke in victims of unexplained stroke at a young age.

AFFIRM established optimal treatment regiments for patients with atrial fibrillation

 

ACES evaluated the role of inflammation in patients with coronary artery disease

 

ELITE the first study to demonstrate the utility of angiotensin receptor blockers in elderly patients with congestive heart failure

 

RELY is an international multicenter trial evaluating the effectiveness of a novel blood thinner, dabigatran (an oral direct thrombin inhibitor) vs. coumadin in patients with atrial fibrillation. This completed study led to the release of the new anticoagulant Pradaxa (dabigatran) in 2010.

 

SCD-HEFT helped establish the utility of defibrillators in patients with ischemic and nonischemic cardiomyopathies

contact us | links | WCA
 

Copyright 2003 Westwood Cardiology Associates, P.A.